BACKGROUND: Glucagon-like peptide 1 (GLP-1) and glucagon share the same precursor molecule proglucagon, but each arises from a distinct posttranslational process in a tissue-specific manner. Recently, it has been shown that GLP-1 is co-expressed with glucagon in pancreatic islet cells. This study was aimed to investigate the progressive changes of GLP-1 versus glucagon production in pancreatic islets during the course of diabetes development. METHODS: Both type 1 (non-obese diabetes mice) and type 2 (db/db mice) diabetes models were employed in this study. The mice were monitored closely for their diabetes progression and were sacrificed at different stages according to their blood glucose levels. GLP-1 and glucagon expression in the pancreatic islets was examined using immunohistochemistry assays. Quantitative analysis was performed to evaluate the significance of the changes. RESULTS: The ratio of GLP-1-expressing cells to glucagon-expressing cells in the islets showed significant, progressive increase with the development of diabetes in db/db mice. The increase of GLP-1 expression was in agreement with the upregulation of PC1/3 expression in these cells. Interestingly, intra-islet GLP-1 expression was not significantly changed during the development of type 1 diabetes in non-obese diabetes mice. CONCLUSIONS: The study demonstrated that GLP-1 was progressively upregulated in pancreatic islets during type 2 diabetes development. In addition, the data suggest clear differences in intra-islet GLP-1 production between type 1 and type 2 diabetes developments. These differences may have an effect on the clinical and pathophysiological processes of these diseases and may be a target for therapeutic approaches.
BACKGROUND:Glucagon-like peptide 1 (GLP-1) and glucagon share the same precursor molecule proglucagon, but each arises from a distinct posttranslational process in a tissue-specific manner. Recently, it has been shown that GLP-1 is co-expressed with glucagon in pancreatic islet cells. This study was aimed to investigate the progressive changes of GLP-1 versus glucagon production in pancreatic islets during the course of diabetes development. METHODS: Both type 1 (non-obese diabetesmice) and type 2 (db/db mice) diabetes models were employed in this study. The mice were monitored closely for their diabetes progression and were sacrificed at different stages according to their blood glucose levels. GLP-1 and glucagon expression in the pancreatic islets was examined using immunohistochemistry assays. Quantitative analysis was performed to evaluate the significance of the changes. RESULTS: The ratio of GLP-1-expressing cells to glucagon-expressing cells in the islets showed significant, progressive increase with the development of diabetes in db/db mice. The increase of GLP-1 expression was in agreement with the upregulation of PC1/3 expression in these cells. Interestingly, intra-islet GLP-1 expression was not significantly changed during the development of type 1 diabetes in non-obese diabetesmice. CONCLUSIONS: The study demonstrated that GLP-1 was progressively upregulated in pancreatic islets during type 2 diabetes development. In addition, the data suggest clear differences in intra-islet GLP-1 production between type 1 and type 2 diabetes developments. These differences may have an effect on the clinical and pathophysiological processes of these diseases and may be a target for therapeutic approaches.
Authors: A M K Hansen; T B Bödvarsdottir; D N E Nordestgaard; R S Heller; C F Gotfredsen; K Maedler; J J Fels; J J Holst; A E Karlsen Journal: Diabetologia Date: 2011-02-25 Impact factor: 10.122
Authors: Helga Ellingsgaard; Irina Hauselmann; Beat Schuler; Abdella M Habib; Laurie L Baggio; Daniel T Meier; Elisabeth Eppler; Karim Bouzakri; Stephan Wueest; Yannick D Muller; Ann Maria Kruse Hansen; Manfred Reinecke; Daniel Konrad; Max Gassmann; Frank Reimann; Philippe A Halban; Jesper Gromada; Daniel J Drucker; Fiona M Gribble; Jan A Ehses; Marc Y Donath Journal: Nat Med Date: 2011-10-30 Impact factor: 53.440
Authors: Anne-Barbara Witte; Per Grybäck; Hans Jacobsson; Erik Näslund; Per Martin Hellström; Jens Juul Holst; Linda Hilsted; Peter Thelin Schmidt Journal: Scand J Gastroenterol Date: 2010-11-30 Impact factor: 2.423
Authors: P Marchetti; R Lupi; M Bugliani; C L Kirkpatrick; G Sebastiani; F A Grieco; S Del Guerra; V D'Aleo; S Piro; L Marselli; U Boggi; F Filipponi; L Tinti; L Salvini; C B Wollheim; F Purrello; F Dotta Journal: Diabetologia Date: 2012-09-11 Impact factor: 10.122
Authors: Oleg G Chepurny; Minos-Timotheos Matsoukas; George Liapakis; Colin A Leech; Brandon T Milliken; Robert P Doyle; George G Holz Journal: J Biol Chem Date: 2019-01-08 Impact factor: 5.157
Authors: Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney Journal: Rev Endocr Metab Disord Date: 2020-08-26 Impact factor: 6.514
Authors: Jon D Adams; Chiara Dalla Man; Marcello C Laurenti; M Daniela Hurtado Andrade; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella Journal: Metabolism Date: 2020-02-08 Impact factor: 8.694
Authors: Darline Garibay; Jon Lou; Seon A Lee; Karolina E Zaborska; Margot H Weissman; Erica Sloma; Leanne Donahue; Andrew D Miller; Andrew C White; M Dodson Michael; Kyle W Sloop; Bethany P Cummings Journal: Cell Rep Date: 2018-04-24 Impact factor: 9.423